Camurus Wins FDA Fast Track Designation for Opioid Addiction Drug

The FDA has granted fast track designation to an injectable opioid addiction drug developed by Camurus.

CAM2038 buprenorphine subcutaneous injection products are being developed as once-weekly and once-monthly formulations, each with multiple doses.  Braeburn in-licensed the drug from Camurus last year for exclusive U.S. rights.